投资25亿美元！阿斯利康全球战略研发中心落地北京

Core Insights - AstraZeneca has officially launched its sixth global strategic R&D center in the BioPark located in Beijing Economic and Technological Development Area [1][3] - The new center is AstraZeneca's second global strategic R&D center in China, aimed at accelerating the development of next-generation innovative drugs by leveraging Beijing's advanced scientific ecosystem and strengths in artificial intelligence [3][6] - The center will collaborate with AstraZeneca's Shanghai R&D center to lead new drug discovery and clinical development, while also expanding partnerships with local clinical trial institutions, universities, and biotech companies [3][6] Investment and Development - In March, AstraZeneca signed an agreement with Beijing's Science and Technology Commission and other local authorities to invest $2.5 billion in establishing the R&D center and high-standard industrialization projects in Beijing [5][6] - The establishment of the R&D center marks a significant step in AstraZeneca's collaboration with Beijing, focusing on R&D innovation, local partnerships, and regional headquarters [6] Ecosystem and Collaboration - The BioPark is attracting major multinational companies such as Eli Lilly, Pfizer, Bayer, and Medtronic, as well as local innovative enterprises, aiming to create a new global hub for pharmaceutical and health cooperation [8] - Future collaborations will strengthen the connection between Beijing and the University of Cambridge, leveraging the resources of both locations to enhance innovation and industrial ecosystems [8] - The biotechnology and health industry in Beijing Yizhuang has a market value of nearly 90 billion yuan, accounting for a significant portion of the city's economy, with 156 innovative drug candidates in clinical stages [8]